Australia's most trustedsource of pharma news
Competition is heating up in Australia's MET inhibitor space for non-small cell lung cancer, with Merck scoring an early win as Novartis closes in.
Please log in to read.
Our old access system is being retired.
Please create a password and click 'Log in' for ongoing access.
Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).
You're here because you requested to reset your password.
Please choose a new password (minimum 8 characters).
To search the News Archive you need to be logged in.
You can choose not to do this now but after November 30, a password will be required.
To learn more about the new-look Pharma in Focus click here.